Nancy Reau to Liver Cirrhosis
This is a "connection" page, showing publications Nancy Reau has written about Liver Cirrhosis.
Connection Strength
1.976
-
The Burden of Rehospitalization for Patients With Liver Cirrhosis. Hosp Pract (1995). 2016; 44(1):60-9.
Score: 0.538
-
Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and Outcomes. J Clin Gastroenterol. 2024 Jan 01; 58(1):91-97.
Score: 0.233
-
An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project. Hepatology. 2022 12; 76(6):1766-1777.
Score: 0.207
-
Liver Diseases During Pregnancy. Clin Liver Dis. 2019 05; 23(2):345-361.
Score: 0.166
-
Updates on hepatitis C virus therapy in the direct-acting antiviral era. Curr Opin Gastroenterol. 2017 May; 33(3):115-119.
Score: 0.146
-
The benefit of paracentesis on hospitalized adults with cirrhosis and ascites. J Gastroenterol Hepatol. 2016 May; 31(5):1025-30.
Score: 0.137
-
Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era. Clin Liver Dis. 2015 Nov; 19(4):591-604, v.
Score: 0.130
-
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 05; 313(17):1736-44.
Score: 0.128
-
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start? Dig Dis Sci. 2015 Oct; 60(10):3130-5.
Score: 0.126
-
Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis. Blood Adv. 2022 10 25; 6(20):5630-5633.
Score: 0.054
-
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. PLoS One. 2018; 13(8):e0196908.
Score: 0.040
-
Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018 Apr; 47(7):1001-1011.
Score: 0.039
-
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015 Dec 31; 373(27):2608-17.
Score: 0.033